Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Canada)

Index « Auteurs » - entrée « Yves Fradet »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Yves Dion < Yves Fradet < Yves Frègnac  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
000920 (2015) Fred Saad [Canada] ; Neal Shore [États-Unis] ; Hendrik Van Poppel [Belgique] ; Dana E. Rathkopf [États-Unis] ; Matthew R. Smith [États-Unis] ; Johann S. De Bono [Royaume-Uni] ; Christopher J. Logothetis [États-Unis] ; Paul De Souza [Australie] ; Karim Fizazi [France] ; Peter F. A. Mulders [Pays-Bas] ; Paul Mainwaring [Australie] ; John D. Hainsworth [États-Unis] ; Tomasz M. Beer [États-Unis] ; Scott North [Canada] ; Yves Fradet [Canada] ; Thomas A. Griffin [États-Unis] ; Peter De Porre [Belgique] ; Anil Londhe [États-Unis] ; Thian Kheoh [États-Unis] ; Eric J. Small [États-Unis] ; Howard I. Scher [États-Unis] ; Arturo Molina [États-Unis] ; Charles J. Ryan [États-Unis]Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302
000C73 (2014) Dana E. Rathkopf [États-Unis] ; Matthew R. Smith [États-Unis] ; Johann S. De Bono [Royaume-Uni] ; Christopher J. Logothetis [États-Unis] ; Neal D. Shore [États-Unis] ; Paul De Souza [Australie] ; Karim Fizazi [France] ; Peter F. A. Mulders [Pays-Bas] ; Paul Mainwaring [Australie] ; John D. Hainsworth [États-Unis] ; Tomasz M. Beer [États-Unis] ; Scott North [Canada] ; Yves Fradet [Canada] ; Hendrik Van Poppel [Belgique] ; Joan Carles [Espagne] ; Thomas W. Flaig [États-Unis] ; Eleni Efstathiou [États-Unis] ; Evan Y. Yu [États-Unis] ; Celestia S. Higano [États-Unis] ; Mary-Ellen Taplin [États-Unis] ; Thomas W. Griffin [États-Unis] ; Mary B. Todd [États-Unis] ; Margaret K. Yu [États-Unis] ; Youn C. Park [États-Unis] ; THIAN KHEOH [États-Unis] ; Eric J. Small [États-Unis] ; Howard I. Scher [États-Unis] ; Arturo Molina [États-Unis] ; Charles J. Ryan [États-Unis] ; Fred Saad [Canada]Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
001D12 (1998) Frans J. M. Debruyne [Pays-Bas] ; Robin Murray [Australie] ; Yves Fradet [Canada] ; Jan E. Johansson [Suède] ; Chris Tyrrell [Royaume-Uni] ; Francesco Boccardo [Italie] ; Louis Denis [Belgique] ; J. Michael Marberger [Autriche] ; Daniel Brune [France] ; Jens Rassweiler [Allemagne] ; Tony Vangeneugden [Belgique] ; Jan Bruynseels [Belgique] ; Monique Janssens [Belgique] ; Peter De Porre [Belgique]Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate

List of associated KwdEn.i

Nombre de
documents
Descripteur
2Advanced stage
2Aged
2Antineoplastic Agents, Hormonal (adverse effects)
2Antineoplastic Combined Chemotherapy Protocols (adverse effects)
2Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
2Chemotherapy
2Disease-Free Survival
2Human
2Humans
2Kaplan-Meier Estimate
2Male
2Metastatic
2Middle Aged
2Proportional Hazards Models
2Prostate cancer
2Prostatic Neoplasms, Castration-Resistant (drug therapy)
2Prostatic Neoplasms, Castration-Resistant (mortality)
2Prostatic Neoplasms, Castration-Resistant (pathology)
2Risk Factors
2Time Factors
2Treatment Outcome
2Treatment efficiency
2Urology
1Abiraterone
1Abiraterone Acetate
1Abiraterone Acetate (adverse effects)
1Abiraterone Acetate (therapeutic use)
1Academisch ziekenhuis
1Acetate
1Adenocarcinoma
1Adverse events
1Alkaline phosphatase
1Androgen blockade
1Androstenes (administration & dosage)
1Androstenes (adverse effects)
1Antiandrogen
1Antiandrogen withdrawal
1Antiandrogen withdrawal effect
1Antiandrogens
1Antihormone
1Antineoplastic Agents, Hormonal (administration & dosage)
1Antineoplastic Agents, Hormonal (therapeutic use)
1Baseline
1Baseline ecog performance status
1Baseline ecog score
1Baseline performance status
1Baseline prognostic factors
1Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology)
1Blood pressure
1Body weight
1Bone Density Conservation Agents (adverse effects)
1Bone Density Conservation Agents (therapeutic use)
1Bone Neoplasms (drug therapy)
1Bone Neoplasms (mortality)
1Bone Neoplasms (secondary)
1Bone pain
1Cancer cells
1Castration
1Clin
1Clin oncol
1Clinical Trials, Phase III as Topic
1Clinical progression
1Clinical trial
1Common reasons
1Comparative study
1Continuous progression
1Cyproterone
1Cyproterone acetate
1Cytochrome P-450 Enzyme Inhibitors (administration & dosage)
1Cytochrome P-450 Enzyme Inhibitors (adverse effects)
1Differentiation therapy
1Disease Progression
1Double-Blind Method
1Drug Administration Schedule
1Ecog
1Ecog performance status
1Elsevier science
1Elteren test
1Endocrine therapy
1Flic
1Freedom fields hospital
1General association
1Group months
1Hair loss
1Hazard ratio
1Heart rate
1Independent prognostic factors
1Istituto nazionale ricerca cancro
1Janssen research foundation
1Landmark analysis
1Less pain
1Liarozole
1Liarozole group
1Liarozole study group
1Life expectancy
1Long term
1Lower risk
1Maccallum cancer institute
1Median
1Median crude

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Yves Fradet" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i  \
                -Sk "Yves Fradet" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Canada
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Yves Fradet
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024